Monoclonal Antibodies in Cancer Therapy: Emerging Products and Markets

Table of Contents

1 Executive Summary

1.1 Introduction

1.2 Scope and Methodology

1.3 Size and Growth of the Market

2 Introduction

2.1 History and Growth of the Cancer Treatment Market: Monoclonal Antibody Discovery

2.2 The Role of Biotechnology in Cancer Treatment

2.3 Monoclonal Antibody Technology

2.4 Industry Structure

2.5 Demographics and Statistics

3 Current Monoclonal Antibodies for Cancer Treatment

3.1 Overview

3.1.1 Description of Cancers with Available Products

3.1.1.1 Breast Cancer

3.1.1.2 Non-Hodgkin�fs Lymphoma

3.2 Description of Products

3.2.1 Bexxar

3.2.2 Herceptin

3.2.3 Rituxan

3.2.4 Zevalin

3.3 Market Size and Growth

3.4 Competitive Analysis

4 Emerging Monoclonal Antibodies for Cancer Treatment

4.1 Overview

4.1.1 Description of Cancers with New Product Opportunities

4.1.1.1 Colon Cancer

4.1.1.2 Head/Neck Cancer

4.1.1.3 Leukemia

4.1.1.4 Lung Cancer

4.1.1.5 Melanoma

4.1.1.6 Multiple Myeloma

4.1.1.7 Ovarian Cancer

4.1.1.8 Pancreatic Cancer

4.1.1.9 Prostate Cancer

4.1.1.10 Stomach Cancer

4.1.1.11 Other Cancers

4.2 Monoclonal Antibody Pipeline (Cancer)

4.2.1 Phase III

4.2.2 Phase II

4.2.3 Phase I

4.2.4 Pre-clinical

4.3 Market and Product Launch Forecasts

4.4 Potential Competitors and Analysis, 2008

5 Issues and Trends Affecting the Monoclonal Antibody Market

5.1 Introduction

5.2 Insurance and Reimbursement Issues

5.3 Global Issues

5.4 Strategic Trends and Issues

5.5 Treatment Costs

5.6 Alliances, Acquisitions and Licensing Agreements

5.7 Marketing and Distribution Trends

5.8 Manufacturing Issues

5.9 Diagnostic Applications of Monoclonal Antibodies, an Overview

6 Total Market Size and Forecast

6.1 Overview

6.2 Total Market Size and Forecast

6.3 Competitor Analysis

6.4 Market Analysis

7 Corporate Profiles for Current Developers/Providers of Monoclonal Antibodies for Cancer Treatment

7.1 Introduction

7.2 Biogen IDEC

7.3 Corixa Corporation

7.4 Genentech

7.5 GlaxoSmithKline

8 Company Profiles for the Emerging Monoclonal Antibody Cancer Treatment Market

8.1 Introduction

8.2 Abgenix

8.3 Amgen

8.4 Bristol-Myers

8.5 CellTech

8.6 ILEX Oncology

8.7 Imclone Systems

8.8 ImmunoGen

8.9 Immunomedics

8.10 MedImmune

8.11 Merck & Company

8.12 Peregrine Pharmaceuticals

8.13 Protein Design Labs

8.14 Unither Pharmaceuticals

8.15 Wyeth

9 Appendix: Company Names and Addresses